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Abstract
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Local delivery of DNA through a hydrogel scaffold would increase the applicability of gene
therapy in tissue regeneration and cancer therapy. However, the delivery of DNA/cationic polymer
nanoparticles (polyplexes) using hydrogels is challenging due to the aggregation and inactivation
of polyplexes during their incorporation into hydrogel scaffolds. We developed a novel process
(termed Caged Nanoparticle Encapsulation or CnE) to load concentrated and unaggregated nonviral gene delivery nanoparticles into various hydrogels. Previously, we showed that PEG
hydrogels loaded with DNA/PEI polyplexes through this process were able to deliver genes both
in vitro and in vivo. In this study, we found that hyaluronic acid and fibrin hydrogels with
concentrated and unaggregated polyplexes loaded through CnE were able to deliver genes in vivo
as well, demonstrating the universality of the process.
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Introduction
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Gene therapy is the genetic modification of cells through the delivery of DNA or RNA (e.g.
small interfering RNA, siRNA), which can up- or down-regulate genes respectively. Gene
therapy can be achieved with the use of modified viruses (viral delivery) or non-viral gene
delivery vectors (non-viral delivery) that encapsulate or condense plasmid DNA or siRNA
into nanoparticles that transport the genetic material into the cell [1–4]. Although non-viral
delivery is generally less efficient than viral delivery in vivo, it has the following
advantages: (1) the large-scale production of non-viral gene delivery nanoparticles can be
more readily accomplished than that for viruses, (2) repeated injection non-viral
nanoparticles is possible since they can be engineered not to elicit a severe immune
response, (3) the risk of insertion mutagenesis is low since the non-viral gene delivery
vectors do not integrate the delivered DNA into the genomic DNA and (4) larger genes can
be delivered since the non-viral vectors can complex with large DNA molecules.
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Local delivery of DNA or siRNA through a hydrogel scaffold would increase the
applicability of gene therapy in tissue regeneration and cancer therapy [5,6]. Genes encoding
for tissue inductive factors can be delivered to the diseased site with the use of a hydrogel
scaffold. DNA is transferred to the infiltrating cells to produce protein factors in situ to
promote tissue regeneration [6,7]. For cancer therapy, lethal genes or siRNAs can be
delivered with a hydrogel scaffold to induce the apoptosis of tumor cells [8]. Naked DNA
was first incorporated into hydrogels, such as collagen [9–11], pluronic-hyaluronic acid
[12], PEG-poly(lactic acid)-PEG [13], alginate [14], oligo(polyethylene glycol) fumarate
[15] and engineered silk elastin [16] for local gene therapy. Although naked DNA
encapsulated in collagen hydrogels was able to promote bone regeneration in vivo [9,17], the
gene transfer efficiency was very low and most of the encapsulated DNA diffused out from
the hydrogel scaffold rapidly. This motivated researchers to use non-viral gene delivery
vectors to condense DNA into nanoparticles. These nanoparticles can both retain the DNA
in the scaffold and significantly enhance the gene transfer efficiency. Cationic peptides,
lipids, or polymers have been used to prepare nanoparticles that were encapsulated into
collagen [18–20], fibrin [21–26], enzymatically degradable PEG hydrogels [27] and PEGhyaluronic acid [22] hydrogels. Although gene delivery has been observed from these
hydrogels, limitations with low DNA loading and low transgene expression motivated us to
find an effective approach for introducing DNA/cationic polymer polyplexes into hydrogel
scaffolds.
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Previously, we reported on a strategy to incorporate concentrated, un-aggregated and highly
active DNA/PEI polyplexes inside polyethylene glycol (PEG) hydrogel scaffolds, termed
Caged Nanoparticle Encapsulation or CnE [28]. The approach utilizes neutral saccharides
(sucrose) and polysaccharides (agarose) to protect the polyplexes from aggregation and
inactivation during lyophilization and hydrogel formation, respectively. Results showed that
matrix metalloproteinase (MMP) degradable polyethylene glycol (PEG) hydrogels with
concentrated DNA/PEI polyplexes loaded through CnE were able to deliver genes in vivo
and induced extensive angiogenesis when genes encoding for VEGF were delivered. In this
report, we investigated whether CnE could be used to introduce active DNA/PEI polyplexes
into charged hyaluronic acid and protein fibrin hydrogels and achieve efficient gene transfer
in vivo. Both HA and fibrin pose extreme challenges in incorporating PEI/DNA polyplexes.
HA is highly negatively charged and would compete with DNA for the positively charged
PEI, causing polyplex decomplexation. Fibrin is a protein that can absorb the polyplexes and
cause aggregation.

Materials and methods
NIH-PA Author Manuscript

Materials
Human fibrinogen, Bovine plasma thrombin and Linear poly(ethylene imine) (25 kDa, PEI)
were bought from Enzyme Research Laboratories, Sigma and Polysciences, respectively.
Vectors expressing vascular endothelial growth factor (pVEGF) [29] and beta-galactosidase
(pβgal) were gifts from Prof. Lonnie Shea’s laboratory (Northwestern University). pVEGF,
has the VEGF gene is inserted in a pcD3.1 vector with a CMV promoter. pβgal has the βgal
gene inserted in a pNGVL1 promoter with a CMV promoter. A Giga Prep kit from Qiagen
was used to expand the plasmid. Sodium hyaluronan (HA) was a kind gift from Genzyme
Corporation (60 KDa MW, Cambridge, MA). All other chemicals were purchased from
Fisher Scientific unless otherwise noted.
Hyaluronic acid modification
Acrylated hyaluronic acid (HA-AC) was prepared as previously described [28]. Briefly, 1.0
g hyaluronic acid was reacted with 18.0 g adipic dihydrazide (ADH) at pH 4.75 in the
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presence of 2.0 g 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC)
overnight and purified through dialysis (8000 MWCO) in DI water for 1 week. 38.8% of the
carboxyl groups were modified with ADH based on the TNBSA assay. One gram of HAADH was reacted with 0.75 g N-Acryloxysuccinimide in HEPES buffer (pH 7.2) overnight
and purified through dialysis in DI water for 1 week. All the primary amines were acrylated
based on the 2,4,6-Trinitrobenzene sulfonic acid (TNBSA, Thermo Scientific) assay
performed following the product manual.
Polyplex lyophilization
Plasmid DNA (0–300 μg) and PEI (0–587 μg) were mixed in 3.5 mL water in the presence
of 35 mg (0.10 mmole) of sucrose (Ultra pure, MP Biomedicals) and incubated at room
temperature for 15 min. Agarose (1.0 mg, UltraPure™ Agarose, Tm = 34.5~37.5 °C,
Invitrogen) in 1.5 mL water was added before lyophilization.
Hydrogels synthesis and characterization
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To load polyplexes into HA hydrogels through CnE, lyophilized polyplexes were
reconstituted with 100 μL HA-AC solution (in 0.3 M triethanolamine or TEOA, pH = 8.0)
containing crosslinker, dithiothreitol (DTT) and gelled through incubation at 37 °C for 30
min. To load polyplexes through the regular encapsulation process, DNA and PEI were
mixed in the HA-AC solution, vortexed for 15 s and incubated for 15 min at room
temperature before adding crosslinker to form hydrogels at 37 °C for 30 min. To encapsulate
polyplexes into fibrin hydrogels through CnE, 100μL fibrinogen solution in PBS (5 mg/mL)
was mixed with lyophilized polyplexes and initiated to form gels at 37°C for 20 min with
thrombin (2 U/mL). For the regular encapsulation, DNA and PEI were mixed and incubated
in fibrin solution for 15 min at room temperature before adding thrombin to form hydrogels
at 37 °C for 20 min. All hydrogels were swelled in PBS for 2-hrs. The swelled gels were
stained with ethidium bromide (12 μM) for 2-hrs before imaging with a fluorescent
microscope (Observer Z1, Zeiss) or a confocal microscope (Leica TCS SP MP) to visualize
the distribution of polyplexes inside hydrogels. To test the DNA release from the hydrogel, a
30 μL hydrogel with polyplexes loaded through CnE was incubated in 200 μL PBS (pH 7.4)
at 37 °C. Medium was collected daily and released DNA was quantified with HOECHST
dye (H33258) [27].
Choriallantoic Membrane (CAM) assay
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CAM assay was performed as previously described [28]. Briefly, fertilized chicken eggs
were released into tissue culture dishes after 3-days of incubation in a 38°C ventilated,
humid egg incubator and were incubated in a sterile humid incubator at 37°C for another 10
days. Hydrogels with polyplexes were placed on the CAM away from major veins and
incubated for 3 additional days. Gross pictures were recorded (Stemi 2000-C, Zeiss) before
the embryo was infused with 1 mL of FITC-dextran (0.5 mg/mL in PBS, Sigma). The CAM
with the hydrogel was cut and fixed in 4% paraformaldehyde for 2-hrs before imaging with
a fluorescent microscope (Observer Z1 Zeiss). Fixed CAM was immersed in 37°C X-gal
solution (5 mM Potassium ferricyanide, 5 mM Potassium ferrocyanide, 1 mM MgCl2, 1 mg/
mL X-Gal (Gold Biotechnology) in PBS) for 48-hrs to visualize the β-Gal expression, which
was recorded with a color camera attached to a dissecting microscope (Stemi 2000-C, Zeiss)

Results
HA and fibrin induced the aggregation of DNA/PEI polyplexes
Directly mixing DNA/PEI polyplexes with a hydrogel precursor solution before gelation
(regular encapsulation) resulted in severe polyplex aggregations (Fig. 1). Due to the soft,
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loose and charged structures, DNA/PEI polyplexes tend to aggregate at high concentrations
or in salt solution during their incorporation into hydrogels. We tested if HA or fibrin induce
polyplex aggregation by measuring the polyplex size using dynamic light scattering (DLS)
in the absence or presence of HA and fibrin molecules. The average diameter of DNA/PEI
polyplexes in water was about 50–100 nm when the DNA concentration was low (5 μg
DNA in 100 μL H2O, N/P = 15). Adding 1% HA shifted the average diameter of the
polyplexes to ~1 μm. Severe aggregations occurred in the presence of 1% HA when the
DNA concentration was increased to 50 μg in 100 μL as shown by appearance of precipitate
and the disappearance of the particles within the solution (Fig. 1A). Polyplexes containing
100 μg DNA (N/P = 15) were observed to aggregate into one large clot inside the 100 μL
HA hydrogel (Fig. 1B). Fibrin proteins also induced polyplex aggregation. The average
diameters of DNA/PEI polyplexes containing 5 or 50 μg DNA (N/P = 15) in 100 μL 5 mg/
mL fibrin solution were about 4.1 and 5.5 μm respectively (Fig. 1C). Large aggregates were
found when 100 μg DNA (N/P = 15) were incorporated into 100 μL fibrin hydrogels (Fig.
1D).
Encapsulating DNA/PEI polyplexes into HA and fibrin hydrogels through CnE
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Caged nanoparticle encapsulation (CnE) was used to introduce DNA/PEI polyplexes into
HA and fibrin hydrogels. Dilute DNA/PEI polyplexes were prepared in the presence of
sucrose and agarose and lyophilized. The lyophilized powder containing polyplexes was
reconstituted with the hydrogel precursor solution before being initiated to form the
hydrogels. Using CnE, up to 300 μg DNA (N/P = 15) was encapsulated into 100 μL HA
hydrogel crosslinked through Michael addition. The polyplexes were stained with ethidium
bromide and visualized through fluorescence microscopy (Fig. 2A–C and G–I) or confocal
microscopy (Fig. 2D–F and J–L). In contrast to the regular encapsulation (Fig. 1), no
polyplex aggregations were found inside the HA hydrogels through CnE. Without DNA, the
hydrogel scaffold had limited auto-fluorescence (Fig. 2A, B). Polyplexes were distributed
throughout the whole gel (Fig. 2B, C). At high magnification, polyplexes were observed to
be suspended as unaggregated nanoparticles (Fig. 2E, F). The distribution of the polyplexes
inside the hydrogels was not completely homogeneous and there were some micro-domains
with dense concentration of polyplexes. However, both inside and outside these microdomains, the polyplexes were unaggregated. Similar distributions were seen when
polyplexes with 50 μg DNA at N/P = 15 were encapsulated in 100 μL 5 or 15 mg/mL fibrin
hydrogels through CnE (Fig. 2G–L). Without DNA, the fibrin hydrogel scaffold had no
fluorescence (Fig. 2G, L). Polyplexes were distributed throughout the whole gel (Fig. 2H, I).
At high magnification, polyplexes were observed to be suspended as unaggregated
nanoparticles (Fig. 2K, L). The fibrin concentrations had no significant influence on the
polyplex distribution.
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For DNA/PEI polyplexes encapsulated in HA hydrogels through CnE, less than 1% DNA in
the hydrogel was released in PBS over 3 days (Fig. 3A). Polyplexes were retained in the 5 or
15 mg/mL fibrin hydrogel as well as shown that no DNA was released in PBS during the 3
days incubation (Fig. 3B).
HA hydrogels with DNA/PEI polyplexes loaded through CnE were able to deliver genes in
vivo
The ability of HA hydrogels loaded with DNA/PEI polyplexes through CnE to mediate gene
transfer in vivo was assessed using a chorionic chick embryo (CAM) assay. Hydrogels
loaded with DNA encoding for β-galactosidase (pβgal) or VEGF (pVEGF) were placed on
top of the CAM. pβgal was transferred from HA gels to cells and resulted in β-galactosidase
gene expression determined from the extensive blue X-gal staining (Fig. 4B), which was not
found when hydrogels containing pVEGF were used (Fig. 4A).
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The delivery of DNA encoding for VEGF was able to induce blood vessel formation in the
CAM assay. HA hydrogels with polyplexes containing pVEGF were placed on top of the
CAM for 3 days. pVEGF was transferred to cells and produced a high concentration of
VEGF at the gel area, which resulted in hyperbranced neovessels (Fig. 5, arrows). VEGFs
diffusing out the gel created a decreasing VEGF gradient around the gel and led to radial
neovessels around the gel (Fig. 5, arrowheads). Gross evaluation of the blood vessels around
the implanted hydrogels showed that hydrogel with no DNA (Fig. 5A) and hydrogel loaded
with DNA polyplexes encoding for β-galactosidase (Fig. 5B) did not result in enhanced
blood vessel formation. However, hydrogel containing DNA encoding for VEGF resulted in
enhanced blood vessel formation around the implant site (Fig. 5C, D, arrow heads).
Increasing the dose of DNA did not increase the level of angiogenesis around the implant.
Evaluation of the blood vessels underneath/inside the hydrogel scaffold after perfusion
showed enhanced micro-vessel formation for all hydrogels that contained DNA/PEI
polyplexes encoding for VEGF (Fig. 5G, H, arrows). Hydrogels with no DNA, or pβgal
resulted in no micro-vessel formation (Fig. 5E, F).
Fibrin hydrogels with DNA/PEI polyplexes loaded through CnE were able to deliver genes
in vivo
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We tested the ability of DNA loaded fibrin hydrogels to deliver genes in vivo using CAM
assay. Extensive X-gal staining was only observed for the 5 and 15 mg/mL hydrogels loaded
with polyplexes containing pβgal indicating successful gene transfer occurred from the
scaffold to the cells (Fig. 6B, C). We examined the density of the X-gal stained cell nucleus
at high magnification (Fig. 6E, F, white arrows). Within the view, the number of stained
nuclei was 0, 9 and 11 for the gel with no DNA, 5 and 15 mg/mL gels with DNA (Fig. 6D–
F), respectively. However, we failed to see significant differences between the 5 and 15 mg/
mL gels after examining a larger area (data not shown).
The delivery of DNA encoding for VEGF was able to induce angiogenesis in the CAM
assay. Gross evaluation of the blood vessels around the implanted hydrogels showed that
hydrogel with no DNA (Fig. 7A) did not result in enhanced blood vessel formation.
However, all hydrogels containing DNA encoding VEGF resulted in enhanced blood vessel
formation around the implant site (Fig. 7B, C, arrow heads). Evaluation of the blood vessels
underneath/inside the hydrogel scaffold after perfusion showed enhanced micro-vessel
formation for all hydrogels that contained polyplexes encoding for VEGF (Fig. 7E, F,
arrows). Hydrogels with no DNA resulted in no micro-vessel formation (Fig. 7D).

Discussion
NIH-PA Author Manuscript

Local delivery of DNA through a hydrogel scaffold can extend the application of gene
therapy to tissue regeneration and cancer therapy [6]. However, the delivery of DNA/
cationic polymer nanoparticles (polyplexes) using hydrogels has not been successful
partially due to the aggregation and inactivation of polyplexes inside hydrogel scaffolds
[28]. To overcome this challenge, we developed a strategy to introduce unaggregated and
highly active DNA/PEI polyplexes to PEG hydrogel scaffolds [28]. Specifically, we have
found that sucrose was able to retain the activity of polyplexes during lyophilization, which
agrees with previous findings [30–32]. We also found that agarose could prevent polyplex
aggregation during the gelation. We hypothesized this was due to an increase in the viscosity
of the gel precursor solution and a caging effect of the agarose polymers to the polyplexes
[28]. MMP degradable PEG hydrogels with concentrated DNA/PEI polyplexes loaded
through CnE were able to deliver genes in vivo. In this study, we used the CnE to load DNA/
PEI polyplexes into HA and fibrin hydrogels and tested their abilities to mediate gene
transfer in vivo. HA and fibrin are extensively used as scaffolds for tissue engineering, tissue
regeneration and wound healing [33,34].
J Control Release. Author manuscript; available in PMC 2012 August 10.
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Due to the large numbers of carboxylic acid groups on the HA backbone, HA polymers
exhibit a high density of negative charge that can interact with the DNA/PEI polyplexes
through two potential mechanisms. HA can neutralize the positive charges at the polyplex
surface and eliminate the repulsive force between the polyplexes, leading to severe
aggregation. Alternatively, HA can interact with the PEI polymers and replace DNA from
the DNA/PEI polyplexes similarly to what is found with heparin, causing decomplexation
[35]. In dilute solution, HAs induced polyplex aggregation as showed by the fact that 1%
HA increased the average diameter of the polyplexe from 50~100 nm to 1.0 μm (Fig. 1A).
In a solution with high concentration of polyplexes, adding 1% HA completely precipitated
the polyplexes (Fig. 1B). Fibrin proteins induced polyplex aggregation as well (Fig. 1C, D).
Through CnE, polyplex aggregations were prevented in both HA and fibrin hydrogels (Fig.
2). The aggregation of nanoparticles occurs through three basic steps [36]. Nanoparticles are
under random motion in solution that leads to frequent collisions. Part of the collisions
results in aggregations when the collided particles fail to separate. We hypothesize that
agarose can slow down the particle motion and reduce particle/particle interactions through
a combination of increasing the viscosity of the hydrogel precursor solution and caging the
polyplexes with the long agarose polymers, which minimizes nanoparticle aggregation.
Although no aggregation was observed (Fig. 2), micro-scale domains displaying higher
concentration of polyplexes were found inside the hydrogel scaffolds. Inside the
microdomains unaggregated polyplexes were found. We hypothesize that these
microdomains are a result of incomplete dissolution of the lyophilized powder during the
formation of hydrogels, which keep the polyplexes trapped inside the microspheres [28].
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Polyplexes were not free to diffuse inside the hydrogels as shown by the fact that no DNA
was released from the HA or fibrin hydrogels in PBS (Fig. 3). Thus hydrogel degradation
was required for the gene transfer from hydrogels to cells, which allowed highly localized
gene delivery in vivo. We speculate that DNA/PEI polyplexes could be released from the
scaffold during the hydrogel degradation uptake by cells surrounding the hydrogel or they
could be uptake by cells infiltrating the scaffold. From our results using a reporter plasmid
encoding for β-galactosidase (Fig. 4 and 6), for HA hydrogels it appears that gene transfer
only occurs in the area of the hydyrogel, indicating that the polyplexes are transfecting either
infiltrating or very near by cells and not diffusion far from the site of implantation. In fibrin
hydrogels transfection is observed at regions further from the implantation site. However,
most of the transfection was still observed in the area of the hydrogel. In contrast, for MMP
degradable PEG hydrogels gene transfer occur mostly at sites adjacent to the implantation
site [28], indicating that for HA and fibrin hydrogels the scaffold retains the polyplexes at
the implantation site and that cells can more easily infiltrate these scaffolds. We speculate
that the trafficking of DNA/PEI polyplexes once internalized by cells occurs through similar
pathways as have been observed for cells cultured in tissue culture plates [37].
Polyplexes encapsulated inside the hydrogels through the CnE process were found highly
active in vivo as shown by the β-galactosidase expression (Fig. 4, 6). To ensure that the
expressed transgene was present at sufficient concentration to induce an angiogenic response
in and around the hydrogel, plasmid DNA encoding for VEGF was entrapped within the
hydrogel using the CnE. An angiogenic response was observed in all CAMs that contained a
hydrogel with pVEGF/PEI polyplexes entrapped through CnE. The angiogenic response
extended out in a radial orientation toward the CAM (Fig. 5 and 7, arrow heads), suggesting
that the expressed VEGF diffused out of the hydrogel area and created a VEGF gradient
with the highest concentration near the hydrogel. In contrast, the vessels observed at the
hydrogel area are highly branched neovessels without preferred orientations (Fig. 5 and 7,
arrows), suggesting that the VEGF concentration at the gel area was high and relatively
constant. We previously demonstrated that the encapsulation of polyplexes through direct
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encapsulation and in the absence of CnE led to extensively aggregated polyplexes that were
not active in vitro or in vivo [28].
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Conclusion
In summary, polyplexes are known to aggregate in HA or fibrin solutions. The CnE process
prevents polyplex aggregation during their incorporation into HA or fibrin hydrogels. HA or
fibrin hydrogels with concentrated polyplexes loaded through CnE were able to deliver
genes in a CAM model.
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Figure 1.

HA or fibrin induced aggregation of polyplexes. (A, C) DNA/PEI polyplexes containing 5 or
50 μg DNA at N/P = 15 were prepared in 100 μL water or 1% HA or 5 mg/mL fibrinogen
solution. The size distributions of the formed polyplexes were measured with DLS. (B, D)
DNA/L-PEI polyplexes containing 100 μg DNA at N/P = 15 were encapsulated in 100 μL
HA (B) or fibrin (D) hydrogels. The DNA was stained with ethidium bromide and visualized
with a fluorecence microscope. Scale bar: 100 μm.
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Figure 2.
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Polyplex distribution in HA and fibrin hydrogels. DNA/PEI polyplexes containing 0 to 300
μg DNA at N/P = 15 were encapsulated in 100 μL HA (A–F) or fibrin (5 or 15mg/mL) (G–
L) hydrogels through CnE. The DNA was stained with ethidium bromide and visualized
with a fluorescence (A–C, G–I) or confocal microscope (D–F, J–L). Scale bar: 50 μm for
(A–C, G–I) and 1 μm for (D–F, J–L).
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Figure 3.

DNA release from HA and fibrin hydrogels. (A) polyplexes containing 100 μg DNA at N/P
= 15 were encapsulated into 100 μL HA hydrogel. The hydrogel was incubated in PBS (pH
7.4) at 37 °C. (B) polyplexes containing 50 μg DNA at N/P = 15 were encapsulated into 100
μL 5 or 15 mg/mL fibrin hydrogel. The hydrogels were incubated in PBS (pH 7.4) at 37 °C.
The released DNA was quantified with HOECHST.
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Figure 4.

DNA loaded HA hydrogels resulted in gene transfer in CAM model. A HA hydrogel with
polyplexes was placed on top of CAM for 3 days. The gel with CAM was cut, fixed and
stained with x-gal solution for 48 hrs. Positive β-galactosidase expression resulted in blue
color. 100 μg pVEGF or pβgal at N/P = 15 was loaded into 100 μL gel. The dashed line
highlights the edge of the hydrogel and “G” indicates the gel area
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Figure 5.
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pVEGF loaded HA hydrogels resulted in enhanced angiogenesis in a CAM model. A HA
hydrogel with polyplexes containing pVEGF was placed on top of the CAM for 3 days.
pVEGF was transferred to cells and produced a high concentration of VEGF at the gel area,
which resulted in hyperbranced neovessels (arrow). VEGF diffusing out the gel created a
decreasing VEGF gradient around the gel and led to radial neovessels around the gel
(arrowheads). (A–D) Gross pictures on the gel edge were recorded before the CAM was
infused with FITC-dextran for fluorescent imaging (E–H) at the gel area. Induced neovessels
were found both around the gel (C–D, arrow heads) and at the gel area (G–H, arrows) with
pVEGF, which were not found in the negative control (No DNA). Polyplexes at N/P = 15
were used. The dashed line highlights the edge of the hydrogel and “G” indicates the gel
area. Scale bar: E–H: 200 μm
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Figure 6.
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DNA loaded fibrin hydrogels resulted in gene transfer in the CAM model. A fibrin hydrogel
with polyplexes was placed on top of CAM for 3 days. The gel with CAM was cut, fixed
and stained with x-gal solution for 48 hrs. Positive β-galactosidase expression resulted in
blue color. (A–C) and (D–F) showed the low and high magnifications, respectively. 50 μg
pβgal at N/P = 15 was loaded to 100μL 5 or 15 mg/mL fibrin gels. The dashed line
highlights the edge of the hydrogel and “G” indicates the gel area. The white arrows in (E
and F) point out some of the stained nucleus.

NIH-PA Author Manuscript
J Control Release. Author manuscript; available in PMC 2012 August 10.

Lei et al.

Page 16

NIH-PA Author Manuscript

Figure 7.

pVEGF loaded fibrin hydrogels resulted in enhanced angiogenesis in a CAM model. A
fibrin hydrogel with polyplexes containing pVEGF was placed on top of the CAM for 3
days. pVEGF was transferred to cells and produced a high concentration of VEGF at the gel
area, which resulted in hyperbranced neovessels (arrow). VEGF diffusing out the gel created
a decreasing VEGF gradient around the gel and led to radial neovessels around the gel
(arrowheads). (A–C) Gross pictures on the gel edge were recorded before the CAM was
infused with FITC-dextran for fluorescent imaging (D–F) at the gel area. Induced neovessels
were found both around the gel (B–C, arrow heads) and at the gel area (E–F, arrows) with
pVEGF, which were not found in the negative control (No DNA). 50 μg pVEGF at N/P = 15
were used for both the 5 and 15 mg/mL gels. The dashed line outlines the edge of the
hydrogel and “G” indicates the gel area. Scale bar: D–F: 200μm.
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